ES3041684T3 - Antibody to hepatitis b surface antigen and use thereof - Google Patents
Antibody to hepatitis b surface antigen and use thereofInfo
- Publication number
- ES3041684T3 ES3041684T3 ES16853117T ES16853117T ES3041684T3 ES 3041684 T3 ES3041684 T3 ES 3041684T3 ES 16853117 T ES16853117 T ES 16853117T ES 16853117 T ES16853117 T ES 16853117T ES 3041684 T3 ES3041684 T3 ES 3041684T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- presented
- antibody
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510647977 | 2015-10-09 | ||
| PCT/CN2016/101560 WO2017059813A1 (zh) | 2015-10-09 | 2016-10-09 | 抗乙肝表面抗原的抗体及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3041684T3 true ES3041684T3 (en) | 2025-11-13 |
Family
ID=58487306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16853117T Active ES3041684T3 (en) | 2015-10-09 | 2016-10-09 | Antibody to hepatitis b surface antigen and use thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10689434B2 (enExample) |
| EP (1) | EP3360896B1 (enExample) |
| JP (2) | JP6949012B2 (enExample) |
| KR (1) | KR102132604B1 (enExample) |
| CN (1) | CN106565840B (enExample) |
| AU (1) | AU2016334290B2 (enExample) |
| BR (1) | BR112018007121A2 (enExample) |
| CA (1) | CA3001231C (enExample) |
| ES (1) | ES3041684T3 (enExample) |
| WO (1) | WO2017059813A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3001231C (en) * | 2015-10-09 | 2022-07-12 | Xiamen University | Antibody against hepatitis b surface antigen and use thereof |
| US11932681B2 (en) | 2018-05-31 | 2024-03-19 | Novartis Ag | Hepatitis B antibodies |
| NZ770866A (en) * | 2018-05-31 | 2025-07-25 | Daiichi Sankyo Co Ltd | Anti-human tlr7 antibody |
| JP7454855B2 (ja) * | 2018-12-21 | 2024-03-25 | 国立大学法人広島大学 | 抗ｐｒｅＳ１抗体およびその用途 |
| WO2020233695A1 (zh) * | 2019-05-23 | 2020-11-26 | 厦门大学 | 抗乙肝病毒新型抗体及其用途 |
| CN111242107B (zh) * | 2020-04-26 | 2021-03-09 | 北京外号信息技术有限公司 | 用于设置空间中的虚拟对象的方法和电子设备 |
| WO2024148263A1 (en) * | 2023-01-06 | 2024-07-11 | Victorian Infectious Diseases Reference Laboratory | Methods and compositions for antibody treatment of hepatitis b infection |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1322761A4 (en) | 2000-10-02 | 2005-03-23 | Korea Res Inst Of Bioscience | HUMANIZED ANTIBODY AGAINST THE HEPATITE B VIRUS SURFACE ANTIGEN AND METHOD OF PREPARING THE SAME |
| CN1560081A (zh) * | 2004-02-17 | 2005-01-05 | 大连帝恩生物工程有限公司 | 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用 |
| US9567390B2 (en) * | 2008-01-23 | 2017-02-14 | Department Of Biotechnology | Humanized high affinity recombinant antibody against Hepatitis B surface antigen |
| KR101072895B1 (ko) * | 2009-12-24 | 2011-10-17 | 주식회사 녹십자 | Ｂ형 간염 바이러스 표면 항원에 특이적으로 결합하는 인간 항체 |
| CN102786592A (zh) * | 2011-05-17 | 2012-11-21 | 傅阳心 | Hbv特异性抗体 |
| KR102106782B1 (ko) | 2012-06-11 | 2020-05-07 | 시아먼 유니버시티 | 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체 |
| CA2878155C (en) * | 2012-07-10 | 2019-01-08 | Green Cross Corporation | An antibody composition for prevention or treatment of mutant hepatitis b virus infection |
| SG10201806025TA (en) * | 2014-01-16 | 2018-08-30 | Mario Umberto Francesco Mondelli | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen |
| CA3001231C (en) * | 2015-10-09 | 2022-07-12 | Xiamen University | Antibody against hepatitis b surface antigen and use thereof |
-
2016
- 2016-10-09 CA CA3001231A patent/CA3001231C/en active Active
- 2016-10-09 CN CN201610879693.5A patent/CN106565840B/zh active Active
- 2016-10-09 JP JP2018518466A patent/JP6949012B2/ja active Active
- 2016-10-09 EP EP16853117.6A patent/EP3360896B1/en active Active
- 2016-10-09 ES ES16853117T patent/ES3041684T3/es active Active
- 2016-10-09 BR BR112018007121-8A patent/BR112018007121A2/pt active Search and Examination
- 2016-10-09 AU AU2016334290A patent/AU2016334290B2/en active Active
- 2016-10-09 KR KR1020187013043A patent/KR102132604B1/ko active Active
- 2016-10-09 WO PCT/CN2016/101560 patent/WO2017059813A1/zh not_active Ceased
- 2016-10-09 US US15/766,593 patent/US10689434B2/en active Active
-
2020
- 2020-12-18 JP JP2020210762A patent/JP2021063092A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3001231A1 (en) | 2017-04-13 |
| WO2017059813A1 (zh) | 2017-04-13 |
| JP6949012B2 (ja) | 2021-10-13 |
| JP2021063092A (ja) | 2021-04-22 |
| AU2016334290A1 (en) | 2018-05-10 |
| CN106565840A (zh) | 2017-04-19 |
| JP2018533937A (ja) | 2018-11-22 |
| CA3001231C (en) | 2022-07-12 |
| KR102132604B1 (ko) | 2020-07-13 |
| US20190389939A1 (en) | 2019-12-26 |
| AU2016334290B2 (en) | 2020-06-18 |
| US10689434B2 (en) | 2020-06-23 |
| EP3360896A4 (en) | 2019-08-28 |
| BR112018007121A2 (pt) | 2018-11-06 |
| CN106565840B (zh) | 2020-09-01 |
| EP3360896B1 (en) | 2025-07-23 |
| EP3360896A1 (en) | 2018-08-15 |
| KR20180084045A (ko) | 2018-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3041684T3 (en) | Antibody to hepatitis b surface antigen and use thereof | |
| ES2789348T3 (es) | Anticuerpos neutralizantes para GP120 y sus usos | |
| ES2973856T3 (es) | Anticuerpos neutralizantes de poliomavirus | |
| CN103483421B (zh) | 用于治疗hbv感染及相关疾病的多肽及抗体 | |
| US10273288B2 (en) | Neutralizing antibodies to Ebola virus glycoprotein and their use | |
| EP3371214A1 (en) | Neutralizing antibodies to hiv-1 gp41 and their use | |
| US12365722B2 (en) | Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope | |
| CN115087673A (zh) | 结合il4r的抗体及其用途 | |
| KR102561555B1 (ko) | Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체 | |
| US20230348568A1 (en) | Epstein-barr virus monoclonal antibodies and uses thereof | |
| US20230272048A1 (en) | Hiv-1 antibodies | |
| CN113549146A (zh) | 针对柯萨奇病毒b1型的单克隆抗体及其用途 | |
| TWI904315B (zh) | 人lifr抗原結合蛋白及其製備方法和應用 | |
| HK40057872A (en) | Neutralizing antibodies to ebola virus glycoprotein and their use | |
| CN119256013A (zh) | 靶向cd26的抗原结合蛋白及其药物应用 |